[{"address1": "700 Quince Orchard Road", "city": "Gaithersburg", "state": "MD", "zip": "20878", "country": "United States", "phone": "240 268 2000", "website": "https://www.novavax.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 1543, "companyOfficers": [{"maxAge": 1, "name": "Mr. John Joseph Trizzino B.S., M.B.A.", "age": 63, "title": "President & COO", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 641216, "exercisedValue": 0, "unexercisedValue": 213608}, {"maxAge": 1, "name": "Mr. James Patrick Kelly C.F.A.", "age": 57, "title": "Executive VP, CFO & Treasurer", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": 644322, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Stanley Charles Erck", "age": 75, "title": "Advisor", "yearBorn": 1948, "fiscalYear": 2022, "totalPay": 1090317, "exercisedValue": 0, "unexercisedValue": 487116}, {"maxAge": 1, "name": "Mr. John Charles Jacobs M.B.A.", "age": 56, "title": "CEO & Director", "yearBorn": 1967, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Richard P. Crowley", "age": 66, "title": "Executive VP & COO", "yearBorn": 1957, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Troy  Morgan Esq., J.D.", "age": 52, "title": "Senior VP & Chief Compliance Officer", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Mark  Casey", "title": "Executive VP, Chief Legal Officer & Corporate Secretary", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erika S. Trahan", "title": "Associate Director of Investor & Public Relations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ian J. Watkins", "age": 60, "title": "Executive VP & Chief Human Resources Officer", "yearBorn": 1963, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Silvia  Taylor M.B.A.", "title": "Executive VP and Chief Corporate Affairs & Advocacy Officer", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 4, "compensationRisk": 4, "shareHolderRightsRisk": 5, "overallRisk": 4, "governanceEpochDate": 1711670400, "compensationAsOfEpochDate": 1672444800, "irWebsite": "http://www.novavax.com/go.cfm?do=Stock.GetQuote", "maxAge": 86400, "priceHint": 4, "previousClose": 4.78, "open": 4.8, "dayLow": 4.61, "dayHigh": 4.85, "regularMarketPreviousClose": 4.78, "regularMarketOpen": 4.8, "regularMarketDayLow": 4.61, "regularMarketDayHigh": 4.85, "beta": 1.581, "forwardPE": 38.75, "volume": 4306874, "regularMarketVolume": 4306874, "averageVolume": 8539656, "averageVolume10days": 4636300, "averageDailyVolume10Day": 4636300, "marketCap": 650781440, "fiftyTwoWeekLow": 3.53, "fiftyTwoWeekHigh": 11.36, "priceToSalesTrailing12Months": 0.66156155, "fiftyDayAverage": 4.6068, "twoHundredDayAverage": 6.34435, "currency": "USD", "enterpriseValue": 362912128, "profitMargins": -0.55409, "floatShares": 125195084, "sharesOutstanding": 139952992, "sharesShort": 48126414, "sharesShortPriorMonth": 54827218, "sharesShortPreviousMonthDate": 1707955200, "dateShortInterest": 1710460800, "sharesPercentSharesOut": 0.3439, "heldPercentInsiders": 0.04998, "heldPercentInstitutions": 0.56321, "shortRatio": 4.04, "shortPercentOfFloat": 0.40080002, "impliedSharesOutstanding": 139952992, "bookValue": -5.139, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -545062016, "trailingEps": -5.41, "forwardEps": 0.12, "pegRatio": 0.09, "lastSplitFactor": "1:20", "lastSplitDate": 1557446400, "enterpriseToRevenue": 0.369, "enterpriseToEbitda": -0.71, "52WeekChange": -0.34877384, "SandP52WeekChange": 0.28136122, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "NVAX", "underlyingSymbol": "NVAX", "shortName": "Novavax, Inc.", "longName": "Novavax, Inc.", "firstTradeDateEpochUtc": 818173800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cdb3cddb-5091-3918-86d6-9b4894e61c6c", "messageBoardId": "finmb_350381", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.65, "targetHighPrice": 38.0, "targetLowPrice": 4.0, "targetMeanPrice": 15.4, "targetMedianPrice": 11.0, "recommendationMean": 2.7, "recommendationKey": "hold", "numberOfAnalystOpinions": 5, "totalCash": 568505024, "totalCashPerShare": 4.062, "ebitda": -510985984, "totalDebt": 280635008, "quickRatio": 0.529, "currentRatio": 0.7, "totalRevenue": 983705024, "revenuePerShare": 9.762, "returnOnAssets": -0.17018, "freeCashflow": -979221888, "operatingCashflow": -713966976, "revenueGrowth": -0.185, "grossMargins": -0.09633, "ebitdaMargins": -0.51945, "operatingMargins": -0.63008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-02"}]